Mutations in the RIPK1 gene responsible for CRIA syndrome

Randomized trial shows benefit of belantamab mafodotin in relapsed/refractory patients

NIH-funded finding may alter policies at hospitals where fresh red cells are preferentially used

The phase II trial found that over 80 percent of men with prostate cancer whose tumors had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib

By shedding light on several unexpected disease clusters and their costs, this work could inform new approaches for managing chronic conditions

Early consultation with an ID specialist associated with 40 percent lower mortality

Comparative RNA sequencing analysis, conducted across four precision medicine studies, was feasible and potentially useful for 68 percent of children with cancer

Recent study is the first to analyze the available data on rare diseases with such precision

A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment

The expansion of immunotherapies is a key trend to watch in cancer research